With their promise to transform disease trajectories, cell and gene therapies (CGTs) are bringing new hope to patients with ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...

DUBLIN--(BUSINESS WIRE)--The "Global Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report by Vector Type (Adenovirus, AAV, Lentivirus), by Application, by Workflow, by ...

JUMET, Belgium, June 9, 2022 /PRNewswire/ -- Exothera S.A., a leading CDMO that specializes in the development and manufacture of viral vectors for vaccines and gene therapies, has developed and is ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Learn how advances in stabilization, automation, and SR-DLS are making PEI-based transient transfection more efficient, ...

Human embryonic kidney (HEK293) cells are the most commonly used cell line to produce viral vectors for gene therapy. Due to the complexity of their production and purification, viral vectors can be ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...